![Bruno Gagnon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bruno Gagnon
Corporate Officer/Principal bij OPTHEA LIMITED
Actieve functies van Bruno Gagnon
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
OPTHEA LIMITED | Corporate Officer/Principal | 01-07-2022 | - |
Loopbaan van Bruno Gagnon
Eerdere bekende functies van Bruno Gagnon
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BIOMARIN PHARMACEUTICAL INC. | Operationeel Directeur | - | - |
EIDOS THERAPEUTICS, INC. | Operationeel Directeur | - | - |
Opleiding van Bruno Gagnon
University of Montréal | Graduate Degree |
Université Laval | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 3 |
Canada | 3 |
Australië | 2 |
Operationeel
Chief Operating Officer | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
OPTHEA LIMITED | Health Technology |
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Eidos Therapeutics, Inc.
![]() Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Bruno Gagnon
- Ervaring